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The interaction between the chemokine stromal cell-derived factor 1 and its receptor CXCR4 plays
an important role in GH production and cell proliferation in normal and tumorous pituitary so-
matotrope cells. Therefore, the chemokine receptor CXCR4 could be an attractive target for an-
titumor drugs in patients with acromegaly. A synthetic antagonist of CXCR4, cyclic pentapeptide
d-Arg3FC131 (c[Gly1-d-Tyr2-d-Arg3-Arg4-Nal5]) significantly inhibited GH production and prolif-
eration of GH3 somatotrope tumor cells in vitro. It also induced apoptosis of GH3 cells through
activationof the caspase-3pathway. Systemic administrationofd-Arg3FC131 inhibited thegrowth
of GH3 cell xenografts in immunodeficient nude mice by inducing apoptosis and suppressing the
proliferation of tumor cells. These results indicate that d-Arg3FC131 might have potential for the
treatment of pituitary tumors producing excess GH in patients with acromegaly. (Endocrinology
152: 536–544, 2011)
Although pituitary tumors associatedwith acromegalyare rarely malignant, elevated levels of GH and IGF-I
cause various cardiovascular, respiratory, endocrine, and
metabolic morbidities (1, 2). Surgery is the only way to
remove all tumor tissues and completely cure the acrome-
galic patient; however, second-line therapies are usually
necessary to postoperatively manage patients with bulky
tumors or to deal with recurrences (3). Three drug classes
are currently available for the treatment of acromegaly:
dopamine agonists, somatostatin receptor ligands (SRLs),
and a GH receptor antagonist. Therapy using SRLs alone
induced 60–70% biochemical control of serum IGF-I (4).
Combined treatment of SRLs with GH receptor antago-
nist achieved95%IGF-I normalization althoughhigh cost
is an issue (3, 5, 6). If a new pharmacological agent tar-
geting different signaling pathways in somatotrope tumor
is developed, it would provide a multimodal approach in
conjunction with current medical agents for the medical
treatment of GH-producing tumors.
The chemokine stromal cell-derived factor-1 (SDF-1)
and its receptor CXCR4 are reported to be involved in
traffickingofhematopoietic precursor cells, infectionwith
HIV, migration and metastasis of cancer cells, and the
development of rheumatoid arthritis (7–11). SDF-1 has
been demonstrated to be expressed in many organs in
mice, including the brain, heart, lung, thymus, liver,
kidney, spleen, stomach, intestine, and bone marrow.
CXCR4 is widely expressed like SDF-1, particularly in
neuronal tissue (12). SDF-1 was originally cloned from a
murine bone marrow stromal cell line (13), and its amino
acid sequences are highly conserved during the evolution,
implying that this substance might play an important bi-
ological role. SDF-1/CXCR4 interactionplays an essential
role in organ-specific growth, survival, and metastasis of
severalmalignancies, including thoseof thebreast, kidney,
prostate, lungandpancreas,melanomas,neuroblastomas,
non-Hodgkin’s lymphoma, multiple myelomas, ovarian
cancers, andmalignant brain tumors (14–18). Several cel-
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lular pathways, including increased cytosolic Ca2, acti-
vated Pyk2, ERK1/2, and large-conductance Ca2-acti-
vated K channels have been reported to involve SDF-1/
CXCR4-associated carcinogenesis (19).The expressionof
SDF-1andCXCR4 inneuronal, astroglial,microglial, and
endothelial cells of the central nervous systemandanterior
pituitary suggests a possible link between this chemokine
andneuroendocrine regulation (12,20,21).Wehave iden-
tified the expression of SDF-1 and CXCR4 in normal and
tumorous rat pituitary cells (22) and the human pituitary
tumors (23). SDF-1/CXCR4 interaction stimulated GH3
cell proliferation andGHsecretion throughERK1/2phos-
phorylation (22), which is consistent with other studies
(19, 24).
Until now, CXCR4 blockade for oncology has moved
from preclinical research into clinical in some malignan-
cies. However, only a few studies concerning the effect of
CXCR4 antagonist on pituitary tumor have been re-
ported. There are many species of CXCR4 antagonist,
including AMD3100, T22, and T140. Each agent has a
different pathway for blocking the CXCR4with different
pharmacokinetics and pharmacodynamics. In T140
[Arg1-Arg2-Nal3-c(Cys4-Tyr5-Arg6-Lys7-d-Lys8-Pro9-
Tyr10-Arg11-Cit12-Cys13)-Arg14], which is one of the
strong CXCR4 antagonists, residues such as Arg2, Nal3,
Tyr5, and Arg14 are the most important for retaining an-
tagonistic activity against CXCR4 (25). Because T140 is
not stable in mouse serum or in rat liver, indispensable
residues (Arg14 in serum; Arg2, Nal3, and Arg14 in liver
homogenates) are inevitably deleted, leading to adramatic
decrease in the efficacy of degraded peptides (26, 27). To
overcome structural instability ofT140, themolecular size
was minimized and cyclic pentapeptide libraries were de-
signed. As a result, FC131 [cyclo(-Arg1-Arg2-Nal3-Gly4-
DTyr5-)] was obtained and showed strong CXCR4-an-
tagonistic activity similar to that of T140 (25, 28). Here,
we hypothesized that the CXCR4 antagonist, cyclic pen-
tapeptide FC131 [c(Gly1-d-Tyr2-Arg3-Arg4-Nal5) and
its isomeric peptides would effectively inhibit prolifera-
tion in pituitary adenoma cell lines and suppress the se-
cretion of GH.
Materials and Methods
Cell culture and treatment
GH3 cells, a rat pituitary tumor cell line from the American
Type Culture Collection (Manassas, VA), were cultured in 5%
CO2 at 37 C in DMEM (Life Technologies, Inc., Gaithersburg,
MD), supplemented with 10% fetal bovine serum (GIBCO-
BRL), 100 U/ml of penicillin and 100 mg/ml of streptomycin
(Invitrogen, Carlsbad, CA). These cells are an established model
for studyingGH gene expression and its molecular mechanisms
(22, 29, 30). Cells were treated with 18 nM SDF-1 (CXCL12;
R&D Systems, Minneapolis, MN) (22), 100 nM of somatosta-
tin-14 (SST, Sigma-Aldrich, St. Louis,MO), or 100 nMof FC131
analogs including FC131, cyclo[Gly1-d-Tyr2-Arg3-Arg4-
Nal5]; d-Arg3FC131, cyclo[Gly1-d-Tyr2-d-Arg3-Arg4-Nal5];
and d-Arg3-d-Nal5FC131, cyclo[Gly1-d-Tyr2-d-Arg3-Arg4-d-
Nal5] (Anygen, Daejeon, Korea; Fig. 1). To determine the con-
centrationof FC131analogs in cell culture study,GH3cellswere
treated with 1, 10, and 100 nM FC131 analogs. The highest
suppressive effect on tumor growth was observed at a concen-
tration of 100 nM. Therefore, further studies were conducted
using 100 nM FC131 analogs.
Generation of recombinant adenoviral vectors
A cassette containing a luciferase gene driven by the human




FIG. 1. Structures of cyclic pentapeptides that function as CXCR4
antagonists. A, FC131; B, d-Arg3FC131; and C, d-Arg3-d-Nal5FC131.
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Fig. 2A)was subcloned intoanadenoviral transferplasmidbased
onpcDNA3 (Invitrogen) (31).The recombinant adenovirus (Ad-
GHp-Luc) was generated as previously described to investigate
the activation of the GH gene in GH3 cells (31).
Luciferase assay
GH3 cells were seeded in 12-well plates at a density of 5
105 cells per well, after which Ad-GHp-Luc (2 plaque forming
units per cell) was inoculated. The infected cells were treated
with CXCR4 antagonists (1  107 M; Anygen) and soma-
tostatin (1  107 M, Sigma-Aldrich) (32) in serum-free me-
dium for 6 h, after which luciferase activity was measured
using a luciferase assay system (Promega Corp., Madison,
WI). Relative light units were determined using a MicroLumat
LB96PEG&Gluminometer (BertholdTechnologies, BadWildbad,
Germany). Luciferase activity was normalized as described else-
where (33).
Quantitative real-time RT-PCR
The amplification primers for the GH gene were designed as
follows: sense, 5-gctgcgttctgcttctcag-3; and antisense, 5-
ccgaggtaccaaacatcagg-3. The cDNAs containing SYBR Green I
fluorescent dye and 1 PCRMasterMix (Takara, Shuzo, Kyoto,
Japan) were amplified using an ABI 7300 sequence detection
system (PerkinElmer Applied Biosystems, Foster City, CA).
The PCR cycling conditions were as follows: 95 C for 5 min,
40 cycles of 95 C for 15 sec, annealing at 56 C for 15 sec, and
extension at 72 C for 1 min. Relative expression levels were
calculated based on the cycle threshold method (22). Target
gene expression levels were normalized to endogenous con-
trols in all experiments, and data were plotted relative to the
control (hormone free) mRNA.
Assessment of cell proliferation
GH3 cells (5  103 cells per well) were seeded on 96-well
plates in serum-free DMEM, and on the next day, different an-
tagonists were treated twice per day. On d 6, cell proliferation
was assessed using a nonradioactive cell proliferation assay (Cell
Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay;
Promega). Optical density was determined at 490 nm, and rel-
ative data are presented as percentages (mean  SD) (34).
Terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL)
Cell apoptosis was evaluated using TUNEL assay kits (Roche
Molecular Biochemicals, Indianapolis, IN) according to the
manufacturer’s protocol. Briefly, GH3 cells were seeded onto
coverslips and incubated in the presence or absence of CXCR4
antagonists (100 nM) for 16 h at 37C. The cells were fixed in 4%
paraformaldehyde and permeabilized with 0.1% Triton X-100
in 0.1% sodium acetate for 2 min on ice, exposed to the DNA-
labeling solution for 60 min at 37 C, and observed using an
Olympus BX51 microscope (Olympus, Tokyo, Japan) with an
Olympus DP71 camera (Olympus) using DP Controller Soft-
ware (Olympus).
Flow cytometry analysis
Weanalyzed the effect ofCXCR4antagonists on the cell cycle
andapoptosis inGH3cells using fluorescence-activated cell sort-
ing. After treating them with CXCR4 antagonists, GH3 cells
(1  106 cells/ml) were harvested and resuspended with 70%
ethanol at 20 C for 2 h. The cells were washed in PBS and
repeatedly resuspended in 0.5 ml propidium iodide (PI, Sigma-






FIG. 2. Effect of CXCR4 antagonists on inhibition of GH gene
expression. A, A recombinant adenovirus (Ad-GHp-Luc) carrying the
luciferase gene driven by the human GH promoter was used. The E3
region was deleted, and the GH gene promoter and luciferase gene
were inserted in place of the E1a region of adenovirus type 5. B,
Transcriptional activities of the GH promoter of GH3 cells infected with
Ad-GHp-Luc after treatment with various antagonists (100 nM of each
reagent) were evaluated using a luciferase reporter system. *, P 
0.001 compared with control. **, P  0.05 compared with the SST-
treated group. C, GH mRNA expression in GH3 cells after
administration of CXCR4 antagonists and SST. Real-time RT-PCR was
performed at 1 h after treatment with antagonists (100 nM).
Glyceraldehyde-3-dehydrogenase served as a reference gene used for
normalization of the GH mRNA level. ***, P  0.05 compared with
control. Results of three independent experiments (B and C) were
averaged and plotted as the mean  SD for triplicate wells. D,
Treatment with d-ArgFC131 decreased the production of GH in GH3
cells. Western blot analysis was performed to determine the amount of
GH production after CXCR4 antagonist (d-ArgFC131, 100 nM)
treatment for 72 h. The gene for -actin was used as a control. E,
Treatment with d-Arg3FC131 and SST decreased the concentration of
GH in GH3 cells cultured media. Western blot analysis for media had
been performed serially for 3 d (100 nM for d-ArgFC131 and SST).
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EDTA, and 0.1%Triton X-100 at room temperature for 30min
in the dark. Fluorescence was detected using the channel for PI.
Western blot analysis
Antagonist-treatedGH3cellswere lysed in radioimmunepre-
cipitation assay buffer (20 mM Tris, pH 7.5; 2 mM EDTA; 150
mM NaCl; 0.5% Triton X-100; 5% phosphatase inhibitors;
0.5% protease inhibitors). Furthermore, GH3 cell cultured me-
dia was collected, concentrated, and dialyzed. Equal amounts
adjusted using a Bradford protein assay kit (Bio-Rad Laborato-
ries, Inc., Richmond, CA) were separated on 10% SDS-PAGE
and transferred to polyvinylidene difluoride membranes. Blots
were probed by using primary antibodies against phosphory-
lated ERK (1:1000; Cell Signaling Technology, Beverly, MA),
phosphoprotein kinase B/Akt (1:1000, Cell Signaling), Bcl-2 (1:
1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), Bcl-6
(1:1000; Santa Cruz Biotechnology, Inc.), caspase-3 (1:1000;
Cell Signaling), or -actin (1:1000; Santa Cruz Biotechnology,
Inc.) as an internal control. Protein bands were visualized using
a second antibody conjugated with horseradish peroxidase and
an enhanced chemiluminescence kit (Cell Signaling).
Animal experiments
Animal experiments were performed using 6-wk-old male
athymic immunodeficient nude mice (Charles River Japan, Inc.,
Yokohama, Japan). Eachgrouphad five animals andwashoused
in an animal room controlled at 23  2 C and 55  5% room
humidity, under a 12-h light, 12-h dark cycle and fed a standard
unrestricted diet. GH-secreting tumor cells were collected,
washed twice with PBS, resuspended in medium, and injected
(2  106 cells) into the flanks of mice at d 0. Then, ip injection
of either a CXCR4 antagonist (1.23 mg/kg body weight), oct-
reotide [Sandostatin (Norvatis, Stein, Switzerland) 1.23 mg/kg
body weight] or PBS was performed twice per day (35). The size
of tumor mass (in mm3) was measured with calipers in three
dimensions (34) and calculated using the following formula:
(3.14 lengthwidth depth)/6. After 30 d of treatment, the
mice were euthanized and tumor masses were removed. All an-
imal studies were approved by the Animal Care and Use Com-
mittee of the Yonsei University College of Medicine. The col-
lected tumors were fixed with 10% neutral buffered formalin
and processed into paraffin blocks. Sections (4 m) were sub-
jected to hematoxylin and eosin (H&E), TUNEL, and Ki-67
staining. After incubation with fluorescent TUNEL reagent and
a primary antibody for Ki-67, specific biotinylated secondary
antibodies (1:100; Vector Laboratories, Burlingame, CA) and
streptavidin-peroxidase (DAKO, Kyoto, Japan) were incubated
sequentially. Diaminobenzidine (Vector Laboratories) was used
as a chromogen, and counterstaining was performed using
hematoxylin.
Statistical analysis
All statistical analyses of differences were performed using
Student’s t test for comparison between two groups or for mul-
tiple comparisons (more than two groups) and compared using
the linear-by-linear association test. P  0.05 was considered
significant. Statistical analyses were performed using SPSS for
Windows software (version 15.0; SPSS Inc., Chicago, IL).
Results
CXCR4 antagonists inhibit the production and
secretion of GH in GH3 pituitary tumor cells
In this study, we tested whether CXCR4 antagonists
were involved in GH release and production in response
to various peptides (SST, CXCR4 antagonists FC131,
cyclo[Gly1-d-Tyr2-Arg3-Arg4-Nal5], d-Arg3FC131, cyclo-
[Gly1-d-Tyr2-d-Arg3-Arg4-Nal5], d-Arg3-d-Nal5FC131
cyclo[Gly1-d-Tyr2-d-Arg3-Arg4-d-Nal5]). We used GH3
cells transduced with adenovirus carrying GH promoter-
driven luciferase gene (Fig. 2A). Luciferase assays revealed
that d-Arg3FC131 (100 nM) and d-Arg3-d-Nal5FC131
(100 nM) significantly decreased the activity of GH pro-
moter (0.02-fold) compared with the control (arbitrary
value of 1), implying that the CXCR4 antagonists
d-Arg3FC131 and d-Arg3-d-Nal5FC131 block GH
production at the transcription level. Luciferase activ-
ities declined by 0.3-fold with antagonist FC131 and
0.4-fold with SST, respectively, compared with the
control group (Fig. 2B).
We next examined the inhibitory effect of CXCR4 an-
tagonists on GH production by quantitative real-time RT-
PCR (RT-PCR) and Western blotting. Application of 100
nM d-Arg3FC131 decreased the GH transcription levels by
0.6  0.1-fold and d-Arg3-d-Nal5FC131 by 0.67  0.2-
fold (Fig. 2C).Western blotting also showed that the protein
levels of GH in GH3 cells were decreased in d-Arg3FC131-
treated GH3 cells in a time-dependent manner (Fig. 2D).
Quantitation of the results from Western blotting (Supple-
mental Fig. 1 published onThe Endocrine Society’s Journals
Online web site at http://endo.endojournals.org) showed
that d-Arg3FC131 (100 nM) significantly suppressed
GH expression levels after 18 h. GH levels in GH3 cell
culture media increased as time went by, whereas treat-
ment with d-Arg3FC131 or SST inhibited GH secretion
from GH3 (Fig. 2E). These results clearly demonstrate
that d-Arg-FC131 inhibits GH production in GH3 pi-
tuitary tumor cells.
CXCR4 antagonists inhibit the proliferation of GH3
pituitary adenoma cells
To determine whether CXCR4 antagonists inhibited
the proliferation of pituitary tumor cells, GH3 cells were
treated with different doses (1–100 nM) of CXCR4 antag-
onists and SST (100 nM). Growth inhibition was observed
after 6 d of treatment. As shown in Fig. 3A, d-Arg3-d-
Nal5FC131 blocked the growth of GH3 cells in a dose-
dependent manner (67.1  13.2% at 10 nM, 59.3 
10.6% in 100 nM; P  0.05 compared with control for
both). The inhibitory effect of d-Arg3FC131 on GH3 cell
proliferation was the most potent (100 nM, 30%  3.8;
P0.01 comparedwith control),much stronger than that
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of SST (100 nM, 65.3%  11; P  0.05 compared with
control) (Fig. 3A). Therefore, d-Arg3FC131 was used for
the next experiments.
Several reports indicated that SDF-1/CXCR4 interac-
tion activates cell proliferation and survival by stimulating
the ERK1/2 and phosphatidylinositol 3-kinase/Akt path-
ways (35). Therefore,we examinedwhether the inhibitory
effect of CXCR4 antagonists on cell proliferation was re-
lated to the phosphorylation of ERK1/2 andAkt.Western
blotting clearly demonstrated that SDF-1 stimulated the
activation of ERK1/2 at 5 and 10 min after treatment and
of Akt at 10, 30, and 60 min after treatment (Fig. 3B).
However, the antagonist d-Arg3FC131 (100 nM) inhib-
ited these activations.
d-Arg3FC131 causes apoptosis
To elucidate the mechanism of CXCR4 antagonist-in-
duced inhibition of cell proliferation, we quantified the
cell population in different parts of the cell cycle and those
undergoing apoptosis using flow cytometry. As shown in
Fig. 4A, cell cycle analysis revealed that treatment with
d-Arg3FC131 (100nM) increased thepercentageof cells in
the G0–G1 phase, indicating partial G1 cell cycle arrest.
Thisarrest lastedforat least72h.Ourstudyalsoshowedthat
d-Arg3Fc131 induced apoptosis in GH3 cells in a time-de-
pendentmanner (Fig. 4A). The proportion of apoptotic cells
(8 3.4%;P 0.05)was significantly increased after treat-
ment with 100 nM d-Arg3Fc131 compared with that of ve-
hicle-treated GH3 cells (1.35 0.8%) at 72 h.
d-Arg3FC131-induced apoptosis was assessed using
TUNELanalysis (Fig. 4B).Thenumberof apoptotic nuclei
B
A
FIG. 3. Effect of CXCR4 antagonists on GH3 cell proliferation.
A, Proliferation of GH3 cells was assessed by nonradioactive cell
proliferation assay. Cell numbers of GH3 cells are represented as a
percentage of those in the nontreated control group. Among CXCR4
antagonists, d-Arg3FC131 (10, 100 nM) and d-Arg3-d-Nal5FC131 (10,
100 nM) inhibited cell proliferation by approximately 30–60%. Results
of three independent experiments were averaged and plotted as the
mean  SD for triplicate wells. *, P  0.001 compared with control.
**, P  0.001 compared with SST-treated group (100 nM). B,
Inhibition of ERK1/2 and Akt phosphorylation by the CXCR4
antagonist, d-Arg3FC131, in GH3 cells. Western blot analysis was
performed to examine the phosphorylation of ERK1/2 and Akt using








FIG. 4. Effects of d-Arg3FC131 on cell cycle progression and
apoptosis in GH3 cells. A, GH3 cells were exposed to d-Arg3FC131
(100 nM) for 72 h, and cell cycle distributions were analyzed by flow
cytometry as described in Materials and Methods. The proportions of
GH3 cells in specific cell cycle phases are shown. P values compared
with control group at 0 h were calculated using linear-by-linear
association. B, Induction of positive TUNEL reactions in GH3 cells after
72 h of treatment with d-Arg3FC131 (100 nM). Green fluorescent
staining indicates TUNEL, and red fluorescence with PI shows the
nuclei of GH3 cells counted to examine cell density. C, Expression of
cleaved caspase-3 and BCL-6 in GH3 cells. Cells were treated with d-
Arg3FC131 (100 nM) for 72 h, and Western blot analysis was
performed to examine apoptotic pathways with specific antibodies; the
gene for -actin was used as a control. FITC, Fluorescein isothiocyante.
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markedly increased after treatment with 100 nM
d-Arg3FC131 for 3 d. Treatment with d-Arg3FC131 in-
duced approximately a 3-fold increase in apoptotic cells
vs. 11.24 4.8% in vehicle-treated cells and 33.4 7.1%
in antagonist-treated cells (P  0.05). Western blot anal-
yses of apoptosis-related genes were then performed to
confirmthis.Expression levelsofBCL-6,BCL-2,BCL-XL,
Bad, Bax, caspase-3, and cleaved caspase-3 were exam-
ined and comparedwithGH3cells treatedwithorwithout
d-Arg3Fc131 (100 nM) for 72 h (Fig. 4C). The amount of
the cleaved formof caspase-3 increased from0%(control)
to 0.8% at 6 h, 1.2% at 12 h, 1.5% at 18 h, 1.1% at 24 h,
0.8% at 48 h, and 0.5% at 72 h (P 0.05 for all), and an
increase of BCL-6 expression was observed at 18 h com-
pared with control. However, treatment with d-Arg3FC131
did not induce any significant alteration in the expression
levels of the BCL family of genes including BCL-2, BCL-
XL, Bad, and Bax.
d-Arg3FC131 inhibits growth and stimulates
apoptosis of GH3 cells in a nude mouse
xenograft tumor model
Based on our findings that the CXCR4 antagonist
d-Arg3FC131 inhibited cell growth and induced apopto-
sis in vitro, we hypothesized that it might suppress tumor
formation by GH-producing pituitary adenoma cells in
immunodeficient nude mice (Fig. 5). GH3 cells were in-
jected sc into male athymic mice as described inMaterials
and Methods. Tumors developed within 15 d in mice in-
jectedwithPBS (as a control). In thed-Arg3FC131-treated
mice, similar to octreotide-treated ones, tumor formation
was delayed bymore than 10 d comparedwith the control
group. The rate of growth and the size of the tumors were
greatly reduced in mice treated with d-Arg3FC131 com-
pared with those treated with PBS. Furthermore, the ad-
ministrationof d-Arg3FC131 significantly decreasedboth
tumor and total body weights (84  1.9 and 28.16 
0.5%, respectively; P  0.05). There were no significant
differences in the inhibition of tumor growth between oc-
treotide- and d-Arg3FC131-treated mice.
We used histology to evaluate the effect of CXCR4
antagonists on tumor growth in the nude mice. H&E
staining of tumor tissues demonstrated that microvessels
filled with erythrocytes were prominent in control tumor
tissue; however, this was rarely seen in d-Arg3FC131-
treated tumors (Fig. 6 upper panel). We stained for Ki-67
to detect cell proliferation and performed TUNEL assays
to examine apoptosis in tumor tissues (Fig. 6).Numbers of
cells positive for Ki-67 expression and TUNEL were
counted using computer-assisted image analysis software
(MetaMorph, version 4.6; Universal ImagingCo., Down-
ingtown, PA). Tumor tissues from mice treated with
d-Arg3FC131 showed less number of cells stainedpositive
for Ki-67 than those from control mice (10.3% vs. 4.4%,
P  0.05; Fig. 6 middle panel), and the proportion of
TUNEL-positive cell nuclei was significantly increased in
the d-Arg3FC131-injected mice (5.6% vs. 1.2% in con-
trols, P 0.05; Fig. 6, lower panel). Thus, d-Arg3FC131
can reduce xenograft tumor size by inducing apoptosis
and inhibiting cell proliferation, consistent with its effects
in vitro.
Discussion
CXCR4 is one of the most widely expressed chemokine




































FIG. 5. Effect of d-Arg3FC131 on the growth of GH3 cells in nude
mice. A, Examples of nude mice bearing GH3 tumor xenografts from
the control, d-Arg3FC131 (1.23 mg/kg body weight), and octreotide
(1.23 mg/kg body weight) treatment groups. Cultured GH3 cells were
collected and injected into the flank of nude mice (1  106 cells). Red
arrows indicate the tumor mass in the flank. Mice were euthanized at
1 month, and the GH3 tumors were isolated. B, Tumor formation in
the nude mouse xenograft model. The size of the tumor was measured
with calipers in three dimensions every 3 d for 1 month. Each point
represents the mean  SD of tumor volumes in 10 mice per group as
described in Materials and Methods. Values for control mice are shown
as blue square, values for d-Arg3FC131-treated mice are shown as
white square, and values for octreotide are shown as red circles. *, P 
0.05 as compared with control. There was no statistical significance
between d-Arg3FC131 and octreotide treatments. C, Comparison of
tumor weights among control mice, d-Arg3FC131-treated mice, and
octreotide-treated mice. *, P  0.05 compared with control.
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tion causes proliferation, migration, invasion, and metas-
tasis of cancer cells as well as promoting angiogenesis in
tumors (7, 17, 18). BothCXCR4 and SDF-1 are expressed
in rat pituitary primary cells and GH3 cell lines. SDF-1/
CXCR4 interaction is also involved in pituitary cell pro-
liferation and GH secretion and production (19, 22, 24).
We also demonstrated CXCR4 expression in human pi-
tuitary tumors, including GH-producing and nonfunc-
tioning tumors (23). These results indicate that CXCR4
antagonists inhibit pituitary cell proliferation and GH se-
cretion, especially in GH-producing pituitary adenomas.
According to the present study, a CXCR4 antagonist,
d-Arg3FC131, appears to have an important role in ac-
romegalic tumor expansion and GH secretion. Among
several synthetic peptides acting as CXCR4 antago-
nists, d-Arg3FC131more strongly inhibited GH release
and cell proliferation than SST in vitro. In immunode-
ficient nude mice, d-Arg3FC131 significantly inhibited
xenograft tumor growth by inducing apoptosis and sup-
pressing cell proliferation. A combined treatment of
d-Arg3FC131 and octreotide (Sandostatin; Novartis,
Pharma AG, Basel, Switzerland) was slightly more ef-
fective in inhibiting GH3-secreting pituitary tumor for-
mation (Supplemental Fig. 2).
Our study demonstrates the putative mechanisms of
d-Arg3FC131 on inhibiting pituitary tumor formation.
First, the interruption of SDF-1/CXCR4 interaction by
competitively binding d-Arg3FC131 blocked the prolif-
eration of pituitary adenoma cells by stimulating phos-
phorylation of ERK1/2 and Akt (phosphatidylinositol
3-kinase pathway).Cell cycles of tumor cellswere arrested
at the G1 checkpoint, as shown by flow cytometry. Sec-
ond, d-Arg3FC131 induced apoptosis of GH3 pituitary
tumor cells throughactivationof the caspase-3, butnot via
the BCL family of genes. Third, tumor formation was de-
layed in the group of nude mice treated with the CXCR4
antagonist d-Arg3FC131 compared with the control
group by suppressing proliferation and induction of apo-
ptosis. Fourth, H&E staining of histology sections sug-
gests that d-Arg3FC131 could play a role in antiangio-
genesis and block tumor formation. Because there are
several reports indicating the proangiogenic functions of
the SDF-1/CXCR4 pathway (36, 37), further experiments
would be interesting.
How CXCR4 antagonists and SDF-1 are associated
with alterations in cell cycles and apoptosis has been in-
vestigated in several types of cells. According to previous
reports, activation of PI3-K and the BCL family of genes
are mainly involved in the intrinsic cell death pathway
caused by treatment with CXCR4 antagonists (11, 38,
39). Our findings are consistent with previous studies in-
dicating that CXCR4 antagonists have dual antiprolifera-
tive effects, leading to cytostatic (growth arrest) and cy-
totoxic (apoptosis) consequences.
Among three drugs that are currently used for the treat-
ment of patients with acromegaly, somatostatin analogs
are widely used as primary agents. However, more than
one third of patients with acromegaly fail to achieve
adequate biochemical control and suppression of tumor
growth with current medications. Our in vivo results
using an animal model suggest that a combined use of
d-Arg3FC131 and somatostatin analogs would exert
synergetic effects on pharmacological therapy for pa-
tients with acromegaly.
In this study, d-Arg3Fc131 was administered to mice
twice daily because of its short half-life in the systemic
circulation. To apply this new agent to patients with ac-
romegaly, additional experiments related to pharmaco-
dynamics, pharmacokinetics, and toxicity need to be
conducted. In addition, the development of long-acting
slow-releasing formulations such as sandostatin long act-
ing repeatable is highly desirable.
In conclusion, here we demonstrated that d-Arg3FC131
effectively induced apoptosis and cell cycle arrest in
GH3-secreting pituitary tumor cells in vitro and inhib-
ited tumor growth in a xenograft mouse model. To-
gether with somatostatin analogs, d-Arg3FC131 might
have potential for the treatment of patients with
acromegaly.
FIG. 6. Histology and immunohistochemistry of tumor tissues from
xenografted nude mice. The left column shows tumor tissues from the
control group, and the right column shows tissues from d-Arg3FC131-
treated mice. The upper panel shows H&E staining. The red-stained
material in tumors from the control group comprises erythrocytes, and
the adjacent structures are blood vessels, which are rarely observed in
tumors from d-Arg3FC131-treated mice. Immunostaining for Ki-67 is
displayed in the middle panel. TUNEL staining is shown in the lower
panel (magnification, 400).
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